ZYVERSA THERAPEUTICS INC (ZVSA) Stock Price & Overview
NASDAQ:ZVSA • US98987D3008
The current stock price of ZVSA is 0.3113 USD. Today ZVSA is down by -43.3%. In the past month the price decreased by -50.74%. In the past year, price decreased by -92.04%.
ZVSA Key Statistics
- Market Cap
- 1.516M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -7.18
- Dividend Yield
- N/A
ZVSA Stock Performance
ZVSA Stock Chart
ZVSA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ZVSA. When comparing the yearly performance of all stocks, ZVSA is a bad performer in the overall market: 99.3% of all stocks are doing better.
ZVSA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ZVSA. The financial health of ZVSA is average, but there are quite some concerns on its profitability.
ZVSA Earnings
ZVSA Forecast & Estimates
8 analysts have analysed ZVSA and the average price target is 122.4 USD. This implies a price increase of 39218.98% is expected in the next year compared to the current price of 0.3113.
ZVSA Groups
Sector & Classification
ZVSA Financial Highlights
Over the last trailing twelve months ZVSA reported a non-GAAP Earnings per Share(EPS) of -7.18. The EPS increased by 99.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.14% | ||
| ROE | -108.77% | ||
| Debt/Equity | 0 |
ZVSA Ownership
ZVSA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.33 | 406.874B | ||
| AMGN | AMGEN INC | 16.52 | 199.203B | ||
| GILD | GILEAD SCIENCES INC | 16.59 | 178.678B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.77 | 116.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 80.332B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.37 | 42.526B | ||
| INSM | INSMED INC | N/A | 30.205B | ||
| NTRA | NATERA INC | N/A | 28.081B | ||
| BIIB | BIOGEN INC | 11.71 | 27.132B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.72 | 20.958B | ||
| MRNA | MODERNA INC | N/A | 20.742B | ||
| EXAS | EXACT SCIENCES CORP | 341.2 | 19.757B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.5B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZVSA
Company Profile
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida and currently employs 7 full-time employees. The company went IPO on 2021-12-21. The firm is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
Company Info
ZYVERSA THERAPEUTICS INC
2200 N. Commerce Parkway, Suite 208
Weston FLORIDA US
Employees: 7
Phone: 17542311688
ZYVERSA THERAPEUTICS INC / ZVSA FAQ
Can you describe the business of ZYVERSA THERAPEUTICS INC?
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida and currently employs 7 full-time employees. The company went IPO on 2021-12-21. The firm is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
Can you provide the latest stock price for ZYVERSA THERAPEUTICS INC?
The current stock price of ZVSA is 0.3113 USD. The price decreased by -43.3% in the last trading session.
What is the dividend status of ZYVERSA THERAPEUTICS INC?
ZVSA does not pay a dividend.
What is the ChartMill rating of ZYVERSA THERAPEUTICS INC stock?
ZVSA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of ZYVERSA THERAPEUTICS INC (ZVSA)?
ZYVERSA THERAPEUTICS INC (ZVSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.18).